TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report report published on Tuesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

Shares of TCON opened at $0.03 on Tuesday. The firm has a fifty day moving average price of $0.04 and a 200 day moving average price of $0.28. The stock has a market cap of $109,802.00, a PE ratio of 0.01 and a beta of 1.37. TRACON Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $14.75.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.